Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid PharmaLUX:ORCHP 59 Return-on-Tangible-Asset is 5.18% as of Mar. 2026, which is 936% above its 10-year median of 0.50. GuruFocus rates LUX:ORCHP with a GF Score™ of 59/100 and a GF Value™ of $4.38. The stock has 10 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Orchid Pharma ranks worse than 59.48% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Orchid Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was $10.25 Mil. Orchid Pharma's average total tangible assets for the quarter that ended in Mar. 2026 was $197.94 Mil. Therefore, Orchid Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.18%.
The historical rank and industry rank for Orchid Pharma's Return-on-Tangible-Asset or its related term are showing as below:
LUX:ORCHP'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -14.7 Med: 0.5 Max: 6.67
Current: 1.17
During the past 13 years, Orchid Pharma's highest Return-on-Tangible-Asset was 6.67%. The lowest was -14.70%. And the median was 0.50%.
LUX:ORCHP's Return-on-Tangible-Asset is ranked worse than 59.48% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs LUX:ORCHP: 1.17
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Orchid Pharma Return-on-Tangible-Asset Related Terms
Orchid Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUX:ORCHP vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.18% mean?
Orchid Pharma (LUX:ORCHP) has a Return-on-Tangible-Asset of 5.18% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orchid Pharma and its competitors. This is 936% above median its historical median of 0.50. According to the industry distribution chart, Orchid Pharma ranks #599 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Orchid Pharma's Return-on-Tangible-Asset too high?
Orchid Pharma's current Return-on-Tangible-Asset of 5.18% is 936% above median its 10-year median of 0.50. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Orchid Pharma's value of 5.18% is 64.4% above this industry median. Based on the distribution chart, Orchid Pharma ranks #599 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orchid Pharma has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #599 out of 1007 companies for Return-on-Tangible-Asset. This places Orchid Pharma in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.15. Orchid Pharma's value of 5.18% is 64.4% above this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 3.15, Orchid Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current Return-on-Tangible-Asset of 5.18% is 64.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orchid Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current Return-on-Tangible-Asset is 5.18%, which is 936% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Return-on-Tangible-Asset of 5.18%. The stock's GF Value™ is $4.38, compared to a current price of $5.45 — trading 24.4% above its estimated fair value. The current Return-on-Tangible-Asset is 5.18%, which is 936% above median its 10-year median of 0.50 and 64.4% above the Drug Manufacturers industry median of 3.15. Orchid Pharma's overall GF Score™ is 59/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Return-on-Tangible-Asset is 5.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 24.4% above its estimated GF Value™ of $4.38.
Key valuation signals for LUX:ORCHP:
Return-on-Tangible-Asset: 5.18% (936% above median its 10-year median of 0.50)
GF Value™: $4.38 vs. price of $5.45 (24.4% above fair value)
Industry Position: 64.4% above the Drug Manufacturers median (#599 of 1007)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
59GF Score
Get the complete analysis for LUX:ORCHP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
